Fig. 3

Patients categorization in the entire cohort based on the most clinically significant variant detected. In the case of multiple mutations present in the same patient, the variant with the higher level of evidence was used for establishing patient’s category. 1A.1: Biomarkers related to on-label treatment, 1A.1R: biomarkers related to resistance to an on-label treatment, 1A.2: biomarkers included in guidelines, 1A.2R: biomarkers related to resistance in a treatment included in guidelines, 1B: biomarkers with strong evidence of correlation to treatment, 2C.1: biomarkers related to off-label treatment, 2C.1: biomarkers related to clinical trials, 2D: biomarkers with preclinical evidence of actionability, 3: biomarkers with unknown actionability, no biomarker: patients with no biomarker available. In the case of colorectal cancer patients, the clinical significance of the RAS wild type phenotype was not considered in this figure